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SUMMARY 
We present toxicity and treatment compliance data from a national cohort of patients with anal 
squamous cell carcinoma managed in accordance with UK guidance using intensity-modulated 
radiation therapy and single-dose mitomycin-C (MMC) with either 5-FU (5-fluorouracil) or 
capecitabine. Similar overall rates of grade 3-4 toxicity were seen with capecitabine/MMC as with 5-
FU/MMC. There were, however, differences in patterns of observed haematological and non-
haematological toxicities. 
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SUMMARY 
We present toxicity and treatment compliance data from a national cohort of patients with anal squamous cell carcinoma 
managed in accordance with UK guidance using intensity-modulated radiation therapy and single-dose mitomycin-C (MMC) 
with either 5-FU (5-fluorouracil) or capecitabine. Similar overall rates of grade 3-4 toxicity were seen with capecitabine/MMC 
as with 5-FU/MMC. There were, however, differences in patterns of observed haematological and non-haematological 
toxicities. 
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ABSTRACT  
 
Purpose: Chemoradiotherapy (CRT) with mitomycin C (MMC) and 5-fluouracil (5-FU) is established as the standard of care 
for the radical management of patients with anal squamous cell carcinoma (ASCC). There is emerging use of the oral 
fluoropyrimidine-derivative capecitabine as an alternative to 5-FU despite limited evidence for its tolerability and toxicity.  
Methods & Materials: A national cohort evaluation of anal cancer management within the United Kingdom National Health 
Service was undertaken between February and July 2015. Toxicity rates were prospectively recorded. For this analysis we 
report ASCC patients managed with intensity modulated radiotherapy (IMRT) and a single dose of MMC with either 5-FU (5-
FU/MMC) or capecitabine (capecitabine/MMC). All were treated with radical intent and in accordance with UK guidance. 
Results: Of the 242 patients received from 40 centres across the UK, 147 met inclusion criteria; 52 of whom were treated with 
capecitabine/MMC, and 95 with 5-FU/MMC. There were no treatment related deaths and there was no overall difference in the 
proportion of patients experiencing any grade 3 or above toxicity between the capecitabine and 5-FU groups (45% vs. 55%; 
p=0.35). However, significantly fewer patients in the capecitabine/MMC group experienced grade 3 haematological toxicity 
(4% vs. 27%; p=0.001). A lower proportion of patients completed their planned chemotherapy course in the capecitabine 
cohort, though this did not reach statistical significance (81% vs. 90%; p=0.21). Median radiotherapy treatment duration was 38 
(IQR 38-39) days for both groups. There was no difference in 1-year oncological outcomes. 
Conclusion:  Capecitabine/MMC resulted in similar levels of grade 3-4 toxicity overall as compared with 5-FU/MMC as CRT 
for ASCC, although there were differences in patterns of observed toxicities with less haematological toxicity with 
capecitabine. Further studies of capecitabine/MMC are required to understand the acute toxicity profile and long term 
oncological outcomes of this combination with IMRT in ASCC. 
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INTRODUCTION 
 
Carcinoma of the anus is a rare cancer, accounting for 2.5% of all digestive malignancies (1,2). It is increasing in frequency 
across the developed world, and is strongly associated with oncogenic subtypes of the human papilloma virus (HPV) (3,4). The 
vast majority of cases are anal squamous cell carcinomas (ASCC) and most present at a localised stage, either in the presence 
or absence of regional lymph node involvement. Treatment is directed towards achieving cure and effective local control whilst 
avoiding the requirement for a colostomy (5). Chemoradiotherapy (CRT) forms the international standard of care, achieving 3-
year local control of between 65-74% (6). 
 
Concurrent CRT with mitomycin-C (MMC) and 5-fluouracil (5-FU) is well established as superior to radiotherapy (RT) alone 
or RT in combination with 5-FU in ASCC (7-9). Efforts to improve outcomes, including the substitution of MMC with 
cisplatin and the introduction of neoadjuvant or adjuvant chemotherapy regimens, have not changed this standard of care (10-
13). There is however no international consensus on the optimal dosing of MMC, with two doses administered to patients in 
both RTOG 8704 and RTOG 9811, in contrast to a single dose used in the ACT I, ACT II and EORTC trials (summarised in 
Supp. Table 1). 
 
Capecitabine is a tumour-activated fluoropyrimidine derivative, administered orally as a twice daily tablet. It provides a 
convenient alternative to 5-FU, which requires continuous infusion and central venous access. In colorectal cancer, 
capecitabine is non-inferior with respect to efficacy and has a comparable toxicity profile to 5-FU both in the adjuvant setting 
and as part of concurrent CRT (14-17). With respect to anal cancer, NCCN, ESMO-ESSO-ESTRO, French Intergroup and 
recent UK intensity-modulated radiation therapy (IMRT) guidelines support the use of capecitabine as an alternative option to 
5-FU in radical CRT (18-21).  However, current evidence for capecitabine in ASCC is derived from single centre studies and a 
number of relatively small phase II trials (22-24). Treatment parameters also vary widely across these studies, with significant 
variation in the use of 3D-RT or IMRT, in radiotherapy dose and in target volume (25-28). 
 
Within the United Kingdom (UK), national guidance provided a framework for the standardisation of IMRT delivery in the 
treatment of anal cancer (29). A nationwide audit was undertaken to assess the implementation of IMRT for ASCC within the 
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UK National Health Service, including prospective collection of toxicity and outcomes (30). We present here comparative 
toxicity and early outcomes data for patients treated with standardised IMRT and either capecitabine/MMC or 5-FU/MMC. 
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MATERIALS & METHODS 
 
Setting 
With the support of the Royal College of Radiologists (RCR), we sought to detail the current management of patients 
diagnosed with anal cancer with respect to national guidance. All 56 centres involved in the delivery of RT within the UK were 
approached and asked to include every patient with confirmed anal cancer managed over a six-month period extending from 9th 
February to 27th July 2015. Data were obtained from 40 (71%) centres.  
 
Population and treatment 
UK IMRT guidance (20) was designed in 2013, converting the two phase technique and fractionation used in the UK ACT2 
trial (12) into a single phase IMRT technique with a simultaneous integrated boost. For T1/2 node negative tumours, the 
primary receives a dose of 50.4Gy and elective nodal regions 40Gy over 28 fractions. For T3/4 or node positive tumours, the 
primary receives 53.2Gy and involved nodes 50.4Gy with elective regions again receiving 40Gy over 28 fractions. The 
guidance includes details on target volume definitions (20) and allows either concurrent 5FU or capecitabine (with a single 
dose of MMC (12mg/m2 day 1) for CRT. Optimal and mandatory constraints are provided for PTV, bladder, small bowel, 
femoral heads, and genitalia. There are no constraints used to minimise bone marrow toxicity. To facilitate a comparison 
between chemotherapy regimens (i.e. standardising the radiotherapy component of treatment) only patients treated in 
accordance with the UK IMRT consensus document were included. Patients had to have received at least one dose of MMC 
and either infusional 5-FU (1000 mg/m2 per day on days 1-4 and 29-32) or daily capecitabine (825 mg m2) concurrently with 
IMRT. Patients who did not receive chemotherapy or who received an alternative treatment regimen were not included. Tissue 
types other than ASCC were excluded. 
 
Data collection 
Data were collected using an online data collection tool that was first piloted in five centres. Each centre was asked to provide 
information relating to patient and tumour demographics, staging investigations and details of chemotherapy and radiotherapy 
treatment, including whether this was completed as planned. A structured toxicity reporting form was completed weekly during 
each patient’s treatment, with an optional report made six weeks after completion of CRT, and subsequently uploaded. 
Clinicians were asked to provide a weekly assessment during and shortly after treatment of the presence or absence of grade 1 
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or above treatment-related toxicity. This was measured against Common Toxicity Criteria for Adverse Events v4.03, 2010 
(CTCAE). The Radiotherapy Oncology Group (RTOG) grading system was used to record skin toxicity.  
 
A subsequent survey was sent to all participating centres for completion between 1st September 2016 to 30th November 2016. 
Details regarding response assessment at 6 months and 1 year, disease status and the presence or absence of a colostomy (and 
reasons thereof) were collected. 
 
Data processing 
All submitted toxicity reports were reviewed by two senior oncologists (XX and XX).  In one patient treated with MMC/5-FU, 
toxicity was retrospectively upgraded to grade 3 due to a resultant interruption in CRT. No retrospective changes to toxicity 
grading for those who received capecitabine/MMC were made. Manual clarification of disease stage using criteria from the 7th 
Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual was undertaken if discordance was noted 
between lymph node involvement and recorded disease stage (31). In line with guidance from the RCR, an extension to the a 
priori planned treatment time of greater than two days was counted as an interruption to radiotherapy treatment (32). The 
maximum toxic effect grade is reported here for each assessed toxicity parameter. 
 
For clinical outcomes, centres were specifically asked whether patients were alive, had a stoma in situ, had recurrent disease or 
had had salvage surgery at 6 months and 1 year from completion of CRT. Patients were deemed ‘relapse-free’ at assessed time-
points in the absence of local recurrence, surgery and/or metastatic disease. Complete response was defined as the absence of 
residual disease or surgery. Colostomy-free survival included all those without a stoma. Patients with a stoma included those 
placed prior to CRT and not reversed, those who underwent salvage surgery and those requiring a stoma for CRT morbidity. 
 
Data analysis 
Data analyses were undertaken using Microsoft Office Excel 2013 (Microsoft Corporation, CA, USA), IBM SPSS Statistics 24 
(IBM Corporation, NY, USA) and Stata Version 15 (StataCorp, TX, USA).  Patient, treatment and toxicity characteristics were 
compared using Fisher’s exact test or the Mann-Whitney U test. To account for any differences in baseline patient and tumour 
factors, a propensity score matching approach was explored. Inverse-probability of treatment weighting (IPTW) was used to 
balance the two treatment groups according to age, sex, the presence of a pre-treatment colostomy, primary tumour site and T-
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stage.(33) This resulted in a balanced sample of 119 patients and presence of grade 3 or 4 toxicity was compared across the 
treatment groups. Treatment effect could not be estimated for the toxicity subgroups with a small number of events or no events 
in one of the treatment groups. Bonferroni correction was applied to account for multiple significance testing. Two-tailed 
significance testing was used at a significance level of p<0.05, unless otherwise stated. 
 
Governance approval 
This evaluation was coordinated through the RCR as part of a national clinical audit programme in which governance approvals 
for participation were acquired locally by each participating centre. In accordance with UK practice for healthcare audits, 
approval for data collection was obtained by each NHS institution’s research and governance board. 
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RESULTS 
 
Patient & tumour characteristics 
Of the 242 cases submitted, 180 were treated with IMRT. One-hundred-and-fifty-seven of these were treated in accordance 
with the UK consensus document. Ten patients were excluded from this analysis; one of whom had a confirmed anal 
adenocarcinoma, four of whom did not receive chemotherapy and five who received a drug combination consisting of cisplatin 
alone (n=1) or in combination with etoposide (n=2) or 5FU (n=2). Fig. 1 provides an overview of the process for participant 
selection. Of the 147 cases included, 52 (35.4%) were treated with capecitabine/MMC, and 95 (64.6%) with 5-FU/MMC. Of 
the high volume centres submitting ten or more patients, four solely used 5-FU/MMC, and two solely used capecitabine/MMC. 
The rationale behind the decision to select capecitabine or 5FU for individual patients within the smaller volume centres is 
unknown. 
 
Summaries of included patient and disease demographics are provided in Tables 1 and 2. Baseline patient characteristics (age, 
smoking history, HIV status and presence of pre-treatment colostomy) were comparable between the groups. Although the 
number of patients undergoing diagnostic PET/CT was significantly higher in the capecitabine group (56% vs. 34%; p=0.01), 
this did not translate into higher stages within this group.  
 
Patients and treatment details 
Data relating to overall radiotherapy treatment time, completion of radiotherapy and the overall number of interruptions to 
radiotherapy were available for all patients. Of the 52 in the capecitabine/MMC group, non-haematological and haematological 
toxicity data were respectively available for 47 (90.4%) and 48 (92.3%) patients. In comparison, of the 95 patients receiving 5-
FU/MMC, non-haematological and haematological toxicity data were available for 71 (74.7%) and 66 (69.5%) patients 
respectively. For those patients for whom we have reported haematological toxicity, weekly data for full blood count (FBC) 
were available for at least five weeks for 45 (93.8%) of the capecitabine group and 51 (77.3%) of the 5-FU group. In the 
capecitabine group, FBC data were available for four weeks in two further patients and for three weeks in a final patient. In the 
5-FU group, FBC data were available for four weeks in five (7.6%) patients and three weeks in five (7.6%) patients. For three 
patients data were available for two weeks (at an interval of greater than two weeks between readings) and for one patient data 
were available for the second week of treatment only.  
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Treatment toxicity  
Overall there was no evidence of a significant difference in rates of grade 3-4 toxicity between the capecitabine/MMC and 5-
FU/MMC treated cohorts (45% vs. 55%; p=0.35). There were no treatment related deaths in either group. Rates of grade 1-4 
toxicity (haematological, gastrointestinal, skin and anal pain) are presented in Table 3. Table 4 details statistical comparisons 
of grade 3/4 toxicity, including following an inverse-probability of treatment weighting (IPTW) analysis.  
 
Treatment Compliance 
Median radiotherapy treatment duration did not differ between treatment cohorts at 38 (IQR 38-39) days for patients receiving 
5-FU and 38 (IQR 38-39) days for those receiving capecitabine. As summarised within Table 5, a similar proportion of patients 
within each studied cohort received the full dose of planned radiotherapy.  
 
A greater proportion of patients completed their planned course of 5-FU/MMC than capecitabine/MMC, though this did not 
reach significance (90% vs. 81%; p=0.21). In the 11 patients for whom capecitabine was dose adjusted, ten of the changes were 
due to toxicity. For four patients this related to gastrointestinal sequelae whilst treatment was discontinued due to 
thrombocytopenia and cardiac chest pain in two patients for each and due to infection in a further instance. In contrast, of the 
ten patients for whom 5-FU was discontinued or dose adjusted, four experienced bone marrow toxicity, one developed 
significant stomatitis and a further patient was diagnosed with acute kidney injury.  
 
Oncological outcomes   
Disease and treatment specific outcomes were submitted in the subsequent survey for 100 of the original 147 patients (42 
(80.8%) treated with capecitabine/MMC and 58 (61.1%) patients who received 5-FU/MMC). At six months, three patients 
treated with capecitabine/MMC had residual disease and a further two had already undergone salvage surgery, giving a six-
month complete response rate of 37/42 (88.1%). In the 5-FU/MMC group, four patients had residual disease at six months and 
a further one patient had undergone salvage surgery, hence 53/58 (91.4%) had a six-month complete response (p=0.74).  
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One year relapse-free rates were not significantly different between groups; 32/42 (76.2%) in the capecitabine/MMC group and 
46/58 (79.3%) in patients receiving 5-FU/MMC (p=0.80). Two patients treated with capecitabine/MMC and four patients in the 
5FU/MMC group had died, all from metastatic anal cancer. 
 
In the capecitabine/MMC group, three of 42 patients required pre-treatment colostomies and at one-year follow-up five had 
undergone salvage surgery, two had died and one required a stoma post-treatment to manage faecal incontinence. In the 5-
FU/MMC group, two of 58 patients required pre-treatment colostomies for symptoms relating to their disease and at one-year 
follow-up, two had undergone salvage surgery, four had died and one had required a post-treatment stoma for CRT morbidity. 
One year colostomy-free survival rates were therefore 31 of 40 patients alive at one year in the capecitabine/MMC group 
(77.5%) and 49 of 54 (90.7%) patients in the 5-FU/MMC group (p=0.09). 
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DISCUSSION 
 
There is a paucity of literature relating to the toxicity of capecitabine when used as a component of CRT for anal cancer. We 
present here toxicity and tolerability data from a national cohort of patients with ASCC managed in accordance with UK 
guidance using IMRT and single-dose MMC with either 5-FU or capecitabine. There were no treatment-related deaths and 
there was no significant difference between the cohorts in median treatment duration, rates of complete response at 6 months or 
those remaining disease free at 1 year. Rates of interruption of RT were comparable. Of those managed with 5-FU/MMC, 10% 
failed to complete planned chemotherapy compared with 20% of those treated with capecitabine/MMC, though this difference 
was not significant. In both groups this was for the most part a consequence of toxicity. The capecitabine/MMC combination 
was associated with reduced haematological toxicity but a non-significant trend for more grade 3-4 diarrhoea when compared 
with 5-FU/MMC.  
 
5-FU/MMC forms the standard of care for concurrent CRT in ASCC, supported by six randomised phase III trials, the largest 
of which (ACT2) randomised 472 patients to the 5-FU/MMC arm (12). By comparison, there are no randomised data informing 
the substitution with capecitabine but the data presented here add to, and are consistent with, those from previously published 
series and a phase II evaluation (summarised in Supp. Table 2). 
 
A recent single-centre analysis of patients with anal cancer managed with IMRT also reported reduced rates of grade ≥3 
haematological toxicity with capecitabine when compared to 5-FU (28). However, the relative incidence of both grade ≥3 
neutropenia/leukopenia (52% vs. 20%) and thrombocytopenia (19% vs. 9%) in both the 5-FU and capecitabine cohorts was 
considerably higher than that described in our series (20% vs. 2% for neutropenia/leucopenia and 14% vs. 0% for 
thrombocytopenia). Potential reasons for this might include the use of an additional dose of MMC, larger doses to the 
prophylactic pelvic field or the higher superior border of the radiotherapy fields. UK guidance suggests the superior border of 
the prophylactic clinical target volume (CTV) be placed 20mm above the inferior aspect of the sacroiliac joint; with a further 
5mm CTV to planned target volume (PTV) margin. In contrast the above series used the RTOG atlas, which suggests the 
superior border of the CTV lies at the bifurcation of the common iliac vessels (approximate bony landmark: sacral promontory) 
and a larger CTV to PTV margin of 7-10mm (34). The haematological toxicity resulted in a significantly greater proportion of 
patients in the 5-FU cohort requiring a treatment break (41% vs. 14%), and in a relatively higher overall requirement for 
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treatment suspension than our series (only 5.7% of those managed with capecitabine and 8.4% of the 5-FU cohort required a 
break due to toxicity). Gastrointestinal toxicity was generally low with only one patient (2%) in the capecitabine/MMC group 
and none of the 5-FU/MMC treated patients experiencing grade 3 diarrhoea. Grade 2 diarrhoea was actually greater in the 5-
FU/MMC group (17% vs 5%). In contrast, we identified a 10% greater incidence of diarrhoea at grade three or above in 
patients managed with capecitabine (17% vs. 7%). 
 
Rates of grade 3 gastrointestinal toxicity were also comparatively low in two prior series. A single-centre analysis of 66 
patients treated with IMRT reported 3% grade 3 gastrointestinal toxicity (25). Similarly, Thind et al describe a 3% frequency of 
diarrhoea and 7.6% stomatitis in a multi-centre series of 66 patients managed with 3D-conformal RT (76%) or IMRT (24%) 
(26). Rates of skin toxicity within the Thind cohort were high at 63%. This compared with 27.6% reported by Meulendijks and 
26% reported in our study. The wide range in radiotherapy doses used is likely to have been a significant contributory factor to 
high rates of dermatitis and only one patient required a dose reduction of capecitabine. Within the cohort described by 
Meulindijks, grade 4 toxicity was present in five cases (9%); two of which were dermatological, two haematological and one 
was gastrointestinal. This is likely a consequence of patients receiving a significantly higher dose than UK Guidance 
recommends (12 patients - 64.8Gy, 6 patients - 59.4Gy). The proportion of patients completing planned chemotherapy was 
similar in both reports to that described within the series reported here. Higher overall rates of grade 3 gastrointestinal toxicity 
within our cohort may also reflect prospective collection of toxicity data in our series. 
  
Two prior phase II studies investigated capecitabine/MMC in CRT for ASCC. The EXTRA trial treated 31 patients with a 
combination of conventional parallel-opposed and 3D conformal pelvic fields (27). Skin (39%) and haematological (9.7% 
neutropenia and 3.2% thrombocytopenia) toxicity was greater than reported here. Only 68% of patients completed capecitabine 
as planned whereas, in our series, a greater proportion of 79% of patients completed their planned course of capecitabine. 
Oliveira et al report on 43 patients managed with capecitabine and MMC, though only 10 (23%) of these received IMRT (the 
remainder receiving 3D-RT (24)). Capecitabine treatment was interrupted in 55.8% of the patients within this cohort and 
discontinued for one in view of grade 4 toxicities. Skin and haematological toxicity were seen in a comparable proportion of 
patients, whereas gastrointestinal toxicities were less common than we have reported.  
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In a report focussed on the use of simultaneous integrated boost-IMRT in anal cancer, Tomasoa et al report comparable 
outcomes with capecitabine to 5-FU, though supporting data is not provided (35). In a further Canadian multi-centre analysis 
published only in abstract form, a significantly lower proportion of patients reported adverse effects with capecitabine than 5-
FU (51% vs. 26%), with a lower incidence of stomatitis (6% vs. 40%) and hand-foot syndrome (1% vs. 8%) (36). These 
patients were however managed with a range of radiotherapy doses and it is not clear what proportion received cisplatin rather 
than MMC as a backbone. A number of additional studies have reported on the use of capecitabine as a component of a 
chemotherapy doublet in anal cancer with either cisplatin, MMC or another chemotherapeutic backbone, though these do not 
report on the specific toxicity profiles of MMC and capecitabine (37-42). 
 
Limitations  
The nature of a national cohort evaluation such as this captures real world data but brings several limitations. Although a 
relatively large cohort by the standards seen in ASCC, the numbers of patients within each cohort limits more sophisticated 
analysis (e.g propensity scoring) to account for potential bias from treatment selection that may have occurred based on patient 
characteristics. Nevertheless, the baseline demographic, staging and tumour demographics are comparable, which strengthens 
the validity of the results presented here. In considering responder bias, to our knowledge there is no systematic difference in 
those centres who chose to respond to the audit compared with those who did not.  
 
With respect to specific categories of data, there were lower proportions of haematological toxicity returned for the 5-FU/MMC 
cohort than the capecitabine/MMC group. The continuous nature of the capecitabine makes weekly blood tests routine whereas 
this is not necessarily the case with 5-FU, which might in part have underestimated the reporting of haematological toxicity in 
the 5-FU/MMC group. It must be noted that despite possible underestimation of haematological toxicity in the 5FU cohort, 
there was a statistically significantly more haematological toxicity in this group. Therefore any additional haematological 
toxicity would serve to increase this statistical difference.  The other factor that could affect the haematological toxicity is the 
use of constraints on the bone marrow. This is not used in the UK and as such no patients would have had bone marrow 
sparing. The use of IMRT has been demonstrated to increase dose to bone marrow and as such consideration of bone marrow 
constraints should be given for future (43,44). 
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The proportion of patients for whom oncological outcomes data were available is relatively low. The follow-up survey 
requesting outcome data from participating centres achieved a 68% response rate. Neither this nor prior analyses are adequately 
powered to conclude on the relative efficacy of capecitabine versus 5-FU. In addition, one-year DFS is unlikely to be adequate 
for outcomes reporting in anal cancer which requires at least two or three-year data. We also cannot in this analysis determine 
whether comparable survival outcomes to 5-FU are achieved by capecitabine when the overall received dose is reduced due to 
toxicity. There is therefore a need for further evidence of long-term outcomes in anal cancer with capecitabine. 
 
Finally, in the absence of adequately powered analyses, non-significant p-values reported here must be interpreted as 
demonstrating no evidence of a difference between groups, rather than conclusive evidence of a lack of a difference between 
groups.  
 
Despite these limitations, the multi-centre cohort presented here is the largest to have been managed with standardised IMRT 
treatment and single-dose MMC that has been reported to-date, and has considerable strengths as a consequence both of its 
national scope, the defined time period over which data were collated and from prospective collection of toxicity data. The 
Cancer Research UK funded PLATO trials (PersonaLising Anal cancer RadioTherapy dOse, ISRCTN88455282) are 
investigating the role of different radiotherapy doses in patients with ASCC and allow either 5-FU/MMC or capecitabine/MMC 
(45). In the ACT5 trial evaluating dose escalation, centres choose to use capecitabine or 5-FU as per centre policy. This will 
provide further information regarding toxicity, compliance and cancer outcomes with tightly controlled quality assurance. 
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CONCLUSION 
 
Data from this national multi-centre cohort using a standardised IMRT technique show similar levels of grade 3-4 toxicity 
overall between either 5-FU or capecitabine in combination with MMC as CRT for ASCC. There were, however, differences in 
patterns of observed haematological and non-haematological toxicities. Whilst the toxicity of CRT with MMC/5-FU is well 
characterised, further studies of MMC/capecitabine are required to understand the acute toxicity profile with IMRT. Early 
oncological outcomes appear comparable but again, prospective studies with longer term follow up are required. 
  
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
17 
 
REFERENCES 
  
1
 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. DOI: 10.3322/caac.21166. 
2
 Wilkinson JR, Morris EJ, Downing A, Finan PJ, Aaravani A, Thomas JD, Sebag-Montefiore D. The rising incidence of anal 
cancer in England 1990-2010: a population-based study. Colorectal Dis 2014;16(7):O234-9. DOI: 10.1111/codi.12553. 
3
 Baricevic I, He X, Chakrabarty B et al. High-sensitivity human papilloma virus genotyping reveals near universal positivity in 
anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Eur J Cancer 2015;51:776-85. 
DOI: 10.1016/j.ejca.2015.01.058. 
4
 Wilkinson JR, Morris EJ, Downing A et al. The rising incidence of anal cancer in England 1990-2010: a population-based 
study. Colorectal Dis 2014;16(7):O234-239. DOI: 10.1111/codi.12553. 
5
 Bentzen AG, Balteskard L, Wanderas EH et al. Impaired health-related quality of life after chemoradiotherapy for anal 
cancer: late effects in a national cohort of 128 survivors. Acta Oncol 2013;52(4):736-44. DOI: 
10.3109/0284186X.2013.770599. 
6
 Spithoff K, Cummings B, Jonker D et al. Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. 
Clin Oncol (R Coll Radiol) 2014;26(8):473-487. DOI: 10.1016/j.clon.2014.03.005. 
7
 UKCCCR Anal Cancer Working Party. Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of 
radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. Lancet 1996;348 (9034):1049-54.  
8
 Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in 
the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research 
and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15(5):2040-49. PMID: 
9164216. DOI: 10.1200/JCO.1997.15.5.2040.  
9
 Flam M, John M, Pajak TF et a. Role of mitomycin in combination with fluouracil and radiotherapy and of salvage 
chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III 
randomized intergroup study. J Clin Oncol 1996;14(9):2527-39. DOI: 10.1200/JCO.1996.14.9.2527. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
18 
 
10
 Chin JY, Hong TS, Ryan DP. Mitomycin in anal cancer: still the standard of care. J Clin Oncol 2012;30(35):4297-301. DOI: 
10.1200/JCO.2012.44.8878. 
11
 Gunderson LL, Winter KA, Ajani JA et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal 
carcinoma: survival relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus 
fluouracil/cisplatin. J Clin Oncol 2012;30(35):4344-4351. DOI: 10.1200/JCO.2012.43.8085. 
12
 James RD, Glynne-Jones R, Meadows HM et al. Mitomycin or cisplatin chemoradiation with or without maintenance 
chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised phase 3, open-label 2x2 factorial 
trial. Lancet Oncol 2013;14(6):516-24. DOI: 10.1016/S1470-2045(13)70086-X. 
13
 Peiffert D, Tournier-Rangeard L, Gerard JP et al. Induction chemotherapy and dose intensification of the radiation boost in 
locally advanced anal canal carcinoma: final analysis of the randomised UNICANCER ACCORD 03 trial. J Clin Oncol 
2012;30:1941-8. DOI: 10.1200/JCO.2011.35.4837. 
14
 Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res 2011;3:79-89. DOI: 
10.2147/CMR.S11250. 
15
 Hofheinz RD, Wenz F, Post S et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal 
cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-88. DOI 10.1016/S1470-
2045(12)70116-X. 
16
 Van Custem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in 
patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106. DOI: 
10.1200/JCO.2001.19.21.4097. 
17
 Allegra CJ, Yothers G, O’Connell MJ et al. Neoadjuvant 5-FU or Capecitabine plus radiation with or without oxaliplatin in 
rectal cancer patients: a phase III randomised clinical trial. J Natl Cancer Inst 2015;107(11):djv248. DOI: 10.1093/jnci/djv248. 
18
 Benson AB 3rd, Arnoletti JP, Bekaii-Saab T et al. Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines. 
J Natl Compr Canc Netw 2012;10(4):449-54. DOI: 10.6004/jnccn.212.0046. 
19
 Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii10-20. DOI: 10.1093/annonc/mdu159. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
19 
 
20
 Muirhead R, Adams R, Gilbert D. National guidance for IMRT in anal cancer. 2015. Available at 
www.analimrtguidance.co.uk. (accessed 18th May 2017). 
21
 Moureau-Zabotto L, Venderely V, Abromwitz L et al. Anal cancer: French Intergroup Clinical Practice Guidelines for 
diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis 
2017;49(8):831-40. DOI: 10.1016/j.dld.2017.05.011. 
22
 Chong LC, Healey T, Michele T, Price TJ. Capecitabine in locally advanced anal cancer, do we need randomised evidence? 
Expert Rev Anticancer Ther 2017;17(5):411-6. DOI: 10.1080/14737140.2017.1302333. 
23
 Souza KT, Pereira AA, Araujo RL et al. Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of 
the anal canal: systematic review and meta-analysis. Ecancermedicalscience 2016;10:699. DOI: 10.3332/ecancer.2016.699. 
24
 Oliveira SC, Moniz CM, Riechlemann R et al. Phase II study of capecitabine in substitution of 5-FU in the 
chemoradiotherapy regimen for patients with localised squamous cell carcinoma of the anal canal. J Gastrointest Cancer 
2016;47:75-81. DOI: 10.1007/s12029-015-9790-4. 
25
 Meulendijks D, Dewit L, Tomasoa NB et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an 
alternative treatment option. Br J Cancer 2014;111:1726-33. DOI: 10.1038/bjc.2014.467. 
26
 Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal 
squamous cell carcinoma. Radiat Oncol 2014;9:124. DOI: 10.1186/1748-717X-9-124. 
27
 Glynne-Jones R, Meadows H, Wan S et al. EXTRA - a multicentre phase II study of chemoradiation using a 5 day per week 
oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Oncol Radiat Oncol Biol Phys 2008;72:119-26. 
DOI: 10.1016/j.ijrobp.2007.12.012.  
28
 Goodman KA, Julie D, Cercek A et al. Capecitabine with Mitomycin reduces acute hematologic toxicity and treatment 
delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer. Int J 
Radiat Oncol Biol Phys 2017;98(5):1087-95. DOI: 10.1016/j.ijrobp.2017.03.022. 
29
 Muirhead R, Adams RA, Gilbert DC, Glynne-Jones R, Harrison M, Sebag-Montefiore D, Hawkins MA. Anal cancer: 
developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clin Oncol (R Coll Radiol) 2014;26(11):720-
1. DOI: 10.1016/j.clon.2014.08.001. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
20 
 
30
 XXXX 
31
 Edge S, Byrd DR, Compton CC et al. Anus. Chapter in: AJCC Cancer Staging Manual, 7th Edition. New York, NY: Springer, 
2010: 165-170. 
32
 Royal College of Radiologists. The timely delivery of radical radiotherapy: standards and guidelines for the management of 
unscheduled treatment interruptions, Third Edition. 2008. Available at 
https://www.rcr.ac.uk/sites/default/files/publication/BFCO%2808%296_Interruptions.pdf. Accessed 1st April 2017. 
33
 Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the 
propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34(28):3661-79. DOI: 
10.1002/sim.6607. 
34
 Myerson RJ, Garofalo MC, Naga IE et al. Elective clinical target volumes for conformal therapy in anorectal cancer: an 
RTOG consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74(3):824-30. DOI: 10.1016/j.ijrobp.2008.08.070. 
35
 Tomosoa B, Meulendijks D, Nijkamp J et al. Clinical outcome in patients treated with simultaneous integrated boost - 
intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of 
the anal canal. Acta Oncologica 2016;55(6):760-766. DOI: 10.3109/0284186X.2015.1124141. 
36
 Yu IS, Cheung WY. Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of 
anal cancer. J Clin Oncol 25;4_suppl:680.  
37
 Bazan JG, Luxton G, Mok EC et al. Normal tissue complication probability modelling of acute hematologic toxicity in 
patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. Int J Radiat Oncol 
Biol Phys 2012;84:700-706. DOI: 10.1016/j.ijrobp.2011.12.072. 
38
 Dewas CV, Maingon P, Dalban C et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical 
benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol 2012;7:201. DOI: 10.1186/1748-717X-7-
201. 
39
 Mitchell MP, Abboud M, Eng C et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: 
outcomes and toxicity. Am J Clin Oncoli 2014;37:461-6. DOI: 10.1097/COC.0b013e31827e52a3. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
21 
 
40
 Call JA, Prendergast B, Jensen LG et al. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-
Institutional Retrospective Cohort Study. Am J Clin Oncol 2016;39(1):8-12. DOI: 10.1097/COC.0000000000000009. 
41
 De Bari B, Jumeau R, Bouchaab H et al. Efficacy and safety of helical tomotherapy with daily image guidance in anal cancer 
patients. Acta Oncologica 2016;55:767-773. DOI: 10.3109/0284186X.2015.1120886. 
42
 Peixoto RD, Wan DD, Schellenberg D, Lim HJ. A comparison between 5-fluouracil/mitomycin and capecitabine/mitomycin 
in combination with radiation for anal cancer. J Gastrointest Oncol 2016;7(4):665-72. DOI: 10.21037/jgo.2016.06.04. 
43
 Mell LK, Schomas DA, Salama JK et al. Association between bone marrow dosimetric parameters and acute hematologic 
toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Rdiat Oncol 
Biol Phys 2008;70(5):1431-7. 
44
 Robinson M, Sabbagh A, Muirhead R et al. Modeling early haematologic adverse events in conformal and intensity-
modulated pelvic radiotherapy in anal cancer. Radiother Oncol 2015;117: 246-51. DOI 10.1016/j.radonc.215.09.009. 
45
 Sebag-Montefiore D, Adams R, Bell S et al. The development of an umbrella trial (PLATO) to address radiation therapy 
dose questions in the locoregional management of squamous cell carcinoma of the anus. Int J Radiat Oncol Biol Phys 
2016;92(2):E164-165. DOI: 10.1016/j.ijrobp.2016.06.1006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
22 
 
FIGURES 
Figure 1: Study profile indicating participant selection from the total audit population. 
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TABLES 
Table 1: Baseline characteristics for patients treated with radical intent using intensity modulated radiotherapy and concurrent 
chemoradiotherapy using mitomycin-C (MMC) and either capecitabine or 5-fluorouracil (5-FU). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analyses were undertaken using Fisher’s-Exact Test. 
 
 
 
 
 
 
 
 
 
 
 
 
   MMC & capecitabine 
n=52 
MMC & 5-FU 
n=95 
 
 No. (%) No. (%) p-value 
Sex    
 Male 18 (34.6) 25 (26.3) 0.34 
 Female 34 (65.4) 70 (73.7)  
Age (years)      
 <65 30 (57.7) 56 (59.0) 1.0 
 ≥65 22 (42.3) 39 (41.0)  
Smoking status     
0.78 
 Current smoker 12 (23.1) 24 (25.3) 
 Ex-smoker 11 (21.2) 17 (17.9) 
 Never smoked 23 (44.2) 33 (34.7) 
 Not known 6 (11.5) 21 (22.1) 
HIV status     
0.65  Positive 3 (5.8) 2 (2.1) 
 Negative 28 (53.8) 36 (37.9) 
 Not tested 21 (40.4) 57 (60.0) 
Pre-treatment colostomy     
 Yes 5 (9.6) 16 (16.8) 0.33 
 No 47 (90.4) 79 (83.2)  
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Table 2: Baseline disease characteristics for patients treated with radical intent using intensity modulated radiotherapy and 
concurrent chemoradiotherapy using mitomycin-C (MMC) and either capecitabine or 5-fluorouracil (5-FU). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analyses were undertaken using Fisher’s-Exact Test. 
 
 
 
 
 
   MMC & capecitabine 
n=52 
MMC & 5-FU 
n=95 
 
 No. (%) No. (%) p-value 
Tumour differentiation      
 Well 4 (8) 5 (5) 0.14 
 Moderately  24 (46) 37 (39)  
 Poorly 11 (21) 37 (39)  
 Unknown 13 (25) 16 (17)  
Staging PET/CT      
 Yes 29 (56) 32 (34) 0.01 
 No 23 (44) 63 (66)  
Primary tumour site       
 Anal canal 40 (77)  75 (79) 0.53 
 Anal verge 3 (6) 9 (9)  
 Distal rectum 5 (10) 5 (5)  
 Peri-anal skin 4 (8) 3 (3)  
 No primary identified 0 (0) 2 (2)  
 Unknown/Other 0 (0) 1 (1)  
T-stage      
 T1 7 (14) 8 (8) 0.58 
 T2 24 (46) 40 (42)  
 T3 10 (19) 27 (28)  
 T4 11 (21) 18 (19)  
 Tx 0 (0) 2 (2)  
N-stage      
 Negative 22 (42) 49 (52) 0.31 
 Positive 30 (58) 46 (48)  
M-stage      
 M0 51 (98) 89 (94) 0.69 
 M1 1 (2) 3 (3)  
 Mx 0 (0) 3 (3)  
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Table 3: Comparison of grades 1-4 toxicity during chemoradiotherapy in the group treated with capecitabine/mitomycin-C 
(MMC) and the group treated with 5-fluorouracil (5-FU)/MMC. 
 
 
n 
G1-4 
n (%) 
G1 
n (%) 
G2 
n (%) 
G3 
n (%) 
G4 
n (%) 
p 
Non-haematological toxicity#  
 Gastrointestinal  
 
Nausea 
Cape/MMC 47 21 (44.7) 15 (31.9) 5 (10.6) 1 (2.1) 0 (0.0) 
0.61 5FU/MMC 71 41 (57.8) 29 (40.9) 9 (12.7) 3 (4.2) 0 (0.0) 
Vomiting 
Cape/MMC 47 6 (12.8) 5 (10.6) 0 (0.0) 1 (2.1) 0 (0.0) 
0.82 5FU/MMC 71 12 (16.9) 9 (12.7) 1 (1.4) 2 (2.8) 0 (0.0) 
Diarrhoea Cape/MMC 47 33 (70.2) 15 (31.9) 10 (21.3) 8 (17.0) 0 (0.0) 0.04 5FU/MMC 71 58 (81.7) 41 (57.8) 12 (16.9) 5 (7.0) 0 (0.0) 
Stomatitis Cape/MMC 47 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.001 5FU/MMC 71 17 (23.9) 9 (12.7) 5 (7.0) 3 (4.2) 0 (0.0) 
 Non-gastrointestinal  
 
Skin 
Cape/MMC 47 46 (97.9) 6 (12.8) 28 (59.6) 12 (25.5) 0 (0.0) 
0.84 5FU/MMC 71 68 (95.8) 5 (7.0) 43 (60.6) 19 (26.8) 1 (1.4) 
Anal pain 
Cape/MMC 47 40 (85.1) 15 (31.9) 16 (34.0) 9 (19.2) 0 (0.0) 
0.27 5FU/MMC 71 60 (84.5) 20 (28.2) 34 (47.9) 6 (8.5) 0 (0.0) 
Haematological toxicity$ 
 
Haemoglobin 
Cape/MMC 48 34 (70.8) 28 (58.3) 5 (10.4) 1 (2.1) 0 (0) 
0.16 5FU/MMC 66 35 (53.0) 31 (47.0) 3 (4.5) 1 (1.5) 0 (0) 
WCC 
Cape/MMC 48 25 (52.1) 20 (41.7) 4 (8.3) 1 (2.1) 0 (0) 
0.04 5FU/MMC 66 37 (56.1) 12 (18.2) 12 (18.2) 11 (16.7) 2 (3.0) 
Platelets 
Cape/MMC 48 28 (58.3) 25 (52.1) 3 (6.3) 0 (0.0) 0 (0.0) 
0.02 5FU/MMC 66 46 (69.7) 27 (40.9) 10 (15.2) 8 (12.1) 1 (1.5) 
 
Key: Cape/MMC: capecitabine & mitomycin-C; 5FU/MMC: 5-fluorouracil & mitomycin-C; G1: grade 1; G2: grade 2; G3: 
grade 3; G4: grade 4; WCC: white cell count. 
All analyses undertaken using Fisher’s exact test.  
$ At an alpha value of 0.05 a Bonferroni adjusted p-value of less than 0.02 was considered significant to account for multiple 
significance testing. 
# At an alpha value of 0.05 a Bonferroni adjusted p-value of less than 0.008 was considered significant to account for multiple 
significance testing. 
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Table 4: Comparison of grade three and four toxicity during chemoradiotherapy seen in the group treated with 
capecitabine/mitomycin-C (MMC) and the group treated with 5-fluorouracil (5-FU)/MMC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
G3 – Grade 3. G4 – Grade 4. WCC: white cell count. 
* Patients who experienced more than one toxic effect are counted once at the highest grade recorded.  
^ p-Values are shown both for statistical analyses undertaken using Fisher’s Exact test and following inverse-probability of 
treatment weighting (IPTW). Treatment groups were balanced according to the following baseline characteristics: age, sex, the 
presence of a pre-treatment colostomy, primary tumour site and T-stage. It was not possible to obtain estimates for the toxicity 
subgroups with a small number of, or no, events in one of the treatment groups.  
$ At an alpha value of 0.05 a Bonferroni adjusted p-value of less than 0.0046 was considered significant to account for multiple 
significance testing. 
# At an alpha value of 0.05 a Bonferroni adjusted p-value of less than 0.01 was considered significant to account for multiple 
significance testing. 
  
 
 
 
 
  MMC & capecitabine 
n=47 (non-haematological) 
n=48 (haematological) 
 
MMC & 5-FU 
n=71 (non-haematological) 
n=66 (haematological) 
 
 
IPTW       
p-value^ No. (%) No. (%) p-value 
Any G3/G4 toxic effect* 21 (45) 39 (55) 0.35 0.19 
Non-haematological*$ 20 (43) 30 (42) 1.00 0.72 
 Gastrointestinal 8 (17) 9 (13) 0.60 0.72 
  Nausea 1 (2) 3 (4) 1.00 0.39 
  Vomiting 1 (2) 2 (3) 1.00 0.7 
  Diarrhoea 8 (17) 5 (7) 0.60 0.12 
  Stomatitis 0 (0) 3 (4) 0.16 - 
  Other 0 (0) 1 (1) 1.00 - 
 Skin 12 (26) 20 (28) 0.83 0.71 
 Anal pain 9 (19) 6 (9) 0.10 0.1 
 Cardiac 2 (4) 1 (1) 0.56 - 
 Other 2 (4) 4 (6) 1.00 0.2 
Haematological*# 2 (4) 18 (27) 0.001 <0.001 
 WCC 1 (2) 13 (20) 0.004 <0.001 
 Platelets 0 (0) 9 (14) 0.01 - 
 Haemoglobin 1 (2) 1 (2) 1.00 0.82 
 Febrile neutropenia 1 (2) 0 (0) 0.42 - 
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Table 5: Comparison of treatment interruptions following chemoradiotherapy with mitomycin-C (MMC) and either capecitabine or 5-fluorouracil (5-FU). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
* Regardless of interruptions. $ Includes requirement for revised radiotherapy planning during treatment, machine failure and public holiday. Statistical analyses were undertaken 
using the Mann-Whitney U and Fisher’s Exact tests. 
 MMC & capecitabine 
n=52 
MMC & 5-FU 
n=95 
 
No. (%) No. (%) p-value 
Median treatment duration 38 days 38 days 1.0 
Radiotherapy Received planned dose* 51 (98.1) 89 (93.7) 0.42 
 Treatment interruptions: ≥1 Interruption 6 (11.5) 14 (14.7) 0.80 
   1-3 Interruptions 5 (9.6) 11 (11.6) 0.94 
   4-6 Interruptions 0 (0.0) 2 (2.1)  
   >6 Interruptions 1 (1.9) 1 (1.1)  
 Reason for treatment 
interruption: 
Toxicity 3 (5.8) 8 (8.4) 1.0 
 Unrelated to toxicity 2 (3.9) 6 (6.3)  
  Not known 1 (1.9) 0 (0.0)  
Chemotherapy Completed as planned 42 (80.8) 85 (90.0) 0.21 
 Reason for not completing 
treatment as planned: 
Toxicity 10 (19.2) 9 (9.5) 1.0 
 Patient choice 1 (1.9) 0 (0.0)  
 Not known 0 (0.0) 1 (1.1)  
Treatment-related deaths  0 (0) 0 (0) 1.0 
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